Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Saturday, May 31, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, NP/PAs, and other HCPs involved in the treatment and management of ovarian cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the role of molecular and biomarker testing—including BRCA, homologous recombination deficiency, and FRα—in guiding personalized treatment decisions for patients with ovarian cancer
- Analyze recent clinical trial data on PARP inhibitors (PARPi), antibody-drug conjugates (ADCs), and novel combination therapies to optimize treatment strategies
- Integrate evolving evidence into clinical practice to optimize maintenance therapy and sequencing of novel therapies in ovarian cancer management
- Develop strategies to proactively manage and mitigate treatment-related toxicities associated with PARPi, ADCs, and immune checkpoint inhibitors in ovarian cancer
Rachel N. Grisham, MD
Associate Attending Physician
Division of Solid Tumor Oncology
Section Head, Ovarian Cancer
Director, Gynecologic Medical Oncology, MSK Westchester
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consulting/Advisory Board: AstraZeneca, Corcept, Genmab, GOG Foundation, GSK, Incyclix, Incyte, SpringWorks, Verastem.
Ramez N. Eskander, MD
Professor of Gynecologic Oncology
Medical Director, Clinical Trials Office
Fellowship Program Director
UC San Diego Moores Cancer Center
La Jolla, CA
Disclosures: Advisory Board: AbbVie, AstraZeneca, Daiichi Sankyo, Eisai, GSK, MSD, Myriad, Nuvectis, Pfizer, PMV Pharma, Regeneron; Honoraria: MSD.
Oladapo Yeku, MD, PhD
Assistant Professor
Harvard Medical School
Director of Translational Research, Gynecologic Oncology Program
Massachusetts General Hospital
Boston, MA
Disclosures: Advisory Board Member: HC Bioscience; Contracted Research: Ascendis Pharma, BioNTech, Immunocore Limited, Merck Sharp & Dohme, ProfoundBio
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.